Antibody-Based Immunotherapeutic Strategies in Colorectal Cancer

Holz, E; Raab, R.; Riethmüller, Gert

doi:10.1007/978-3-642-80035-1_21

Cited by 5 publications

(3 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, tumor cells can be eliminated in a very selective manner in comparison with the commonly available cancer treatment methods such as chemotherapy. Moreover, antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) are also other mechanisms by which mAbs mediate the elimination of their target cells (10). In these mechanisms, mAbs can activate the complement or engage the effector cells of the immune systems to destroy and eliminate tumor cells towards whose cell surface antigens the mAbs have binding affinity (10).…”

Section: Contextmentioning

confidence: 99%

“…Moreover, antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) are also other mechanisms by which mAbs mediate the elimination of their target cells (10). In these mechanisms, mAbs can activate the complement or engage the effector cells of the immune systems to destroy and eliminate tumor cells towards whose cell surface antigens the mAbs have binding affinity (10). mAbs have also been utilized for redirection purposes.…”

Section: Contextmentioning

confidence: 99%

See 1 more Smart Citation

The Potential Applicability of Single-Domain Antibodies (VHH): From Checkpoint Blockade to Infectious Disease Therapy

Kozani

Rahbarizadeh

2021

Trends in Med Sci

View full text Add to dashboard Cite

: Monoclonal antibodies (mAbs) have demonstrated promising clinical efficacy in various therapeutic fields over the past decades. However, their size has emerged as the most restricting factor limiting their application in antibody-drug conjugate platforms or antibody-redirected delivery systems. This limitation was mainly due to the inability of these platforms to penetrate the tumor site and reach their intended destination. Single-domain antibodies, also known as VHHs or nanobodies®, are known as promising alternatives capable of addressing the drawbacks of conventional full-sized antibodies. Alongside a great level of affinity and selectivity towards their target, the small size of nanobodies, which is about 15 kDa, their capability for tissue penetrance, the significant level of stability, their simple and cost-friendly manufacturing process, and fleeting half-life in the circulation system, are all among the reasons that have made them suitable candidates for the development of various types of therapies. In this review, we briefly discuss the application of nanobodies in checkpoint blockade therapy and nanobody-drug conjugate platforms. We also discuss nanobody-assisted redirection of various types of delivery systems carrying different types of cargoes. In the last section, we underline the promising and effective application of nanobodies in the fight against infectious diseases.

show abstract

Section: Contextmentioning

confidence: 99%

Section: Contextmentioning

confidence: 99%

The Potential Applicability of Single-Domain Antibodies (VHH): From Checkpoint Blockade to Infectious Disease Therapy

Kozani

Rahbarizadeh

2021

Trends in Med Sci

View full text Add to dashboard Cite

show abstract

“…Antibody-based immunotherapy of cancer includes five basic strategies involving antibodies conjugated with 1) isotope, 2) chemotherapeutic drug, 3) toxin, 4) cytokine, and finally 5) anti-bodies per se mediated their anti-tumor effect by ADCC, complement or idiotypic network. Several recent reviews describe the different approaches (Wilder et al 1996, Holz et al 1996, Bodey et al 1996. Some of the more promising concepts and clinical trials, particularly those relevant to colorectal cancer, will be described.…”

Section: Antibody-based Immunotherapy Of Cancer With Emphasis On Colomentioning

confidence: 99%